Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer.

[1]  S. Miyoshi,et al.  New prognostic indicator for non‐small‐cell lung cancer, quantitation of thymidylate synthase by real‐time reverse transcription polymerase chain reaction , 2003, International journal of cancer.

[2]  M. Fukushima,et al.  Quantitative Measurement of Thymidylate Synthase and Dihydropyrimidine Dehydrogenase mRNA Level in Gastric Cancer by Real‐time RT‐PCR , 2002, Japanese journal of cancer research : Gann.

[3]  T. Koga,et al.  Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues , 2002, International Journal of Clinical Oncology.

[4]  H. Wada,et al.  Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p‐stage I nonsmall‐cell lung cancer , 2002, Journal of surgical oncology.

[5]  M. Fukushima,et al.  Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. , 2002, Anticancer research.

[6]  M. Fukushima,et al.  Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil. , 2001, Lung cancer.

[7]  M. Fukushima,et al.  Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa. , 2001, International journal of oncology.

[8]  M. Fukushima,et al.  Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. , 2000, International journal of oncology.

[9]  S. Groshen,et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  Kangsheng Wang,et al.  Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. , 2000, Analytical biochemistry.

[11]  M. Fukushima,et al.  Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. , 1999, Anticancer research.

[12]  A. Fujioka,et al.  Relationship between Protein Levels and Gene Expression of Dihydropyrimidine Dehydrogenase in Human Tumor Cells during Growth in Culture and in Nude Mice , 1998, Japanese journal of cancer research : Gann.

[13]  H. Wada,et al.  Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC). , 1998, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[14]  J. Mirjolet,et al.  Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity. , 1998, British Journal of Cancer.

[15]  M. Fukushima,et al.  A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance , 1998, Cancer.

[16]  S. Groshen,et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Fukushima,et al.  Preparation of the antibodies against recombinant human thymidylate synthase for the detection of its intratumoral levels and the application to sensitivity-study of 5-fluorouracil. , 1997, Oncology reports.

[18]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[19]  H. Wada,et al.  Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Groshen,et al.  Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Milano,et al.  Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  P. Johnston,et al.  Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.

[23]  G. Milano,et al.  A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. , 1994, European journal of cancer.

[24]  R. Diasio,et al.  Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. , 1990, Cancer research.

[25]  E B Cox,et al.  Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.

[26]  Amanda,et al.  Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. , 1980, The Journal of biological chemistry.

[27]  P. Danenberg.  Thymidylate synthetase - a target enzyme in cancer chemotherapy. , 1977, Biochimica et biophysica acta.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .